Volume | 981,079 |
|
|||||
News | - | ||||||
Day High | 40.97 | Low High |
|||||
Day Low | 40.185 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Halozyme Therapeutics Incorporated | HALO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
40.36 | 40.185 | 40.97 | 40.86 | 39.91 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
16,057 | 981,079 | $ 40.70 | $ 39,926,289 | - | 29.85 - 45.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:40:11 | 16 | $ 40.95 | USD |
Halozyme Therapeutics (HALO) Options Flow Summary
Halozyme Therapeutics Incorporated Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.18B | 126.82M | - | 829.25M | 281.59M | 2.22 | 18.40 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Halozyme Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HALO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 38.76 | 40.97 | 37.965 | 39.18 | 883,541 | 2.10 | 5.42% |
1 Month | 41.09 | 41.355 | 37.73 | 38.98 | 845,586 | -0.23 | -0.56% |
3 Months | 35.58 | 42.64 | 34.36 | 39.50 | 996,725 | 5.28 | 14.84% |
6 Months | 35.37 | 42.82 | 33.15 | 37.83 | 1,170,464 | 5.49 | 15.52% |
1 Year | 31.09 | 45.00 | 29.85 | 37.74 | 1,076,215 | 9.77 | 31.42% |
3 Years | 47.56 | 59.46 | 29.85 | 41.06 | 1,100,552 | -6.70 | -14.09% |
5 Years | 16.72 | 59.46 | 12.71 | 34.84 | 1,198,376 | 24.14 | 144.38% |
Halozyme Therapeutics Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |